|
1
|
Siddiqui M and Rajkumar SV: The high cost
of cancer drugs and what we can do about it. Mayo Clin Proc. 87:pp.
935–943. 2012; View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pantziarka P, Bouche G, Meheus L, Sukhatme
V, Sukhatme VP and Vikas P: The repurposing drugs in oncology
(ReDO) project. Ecancermedicalscience. 8:4422014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pantziarka P, Sukhatme V, Bouche G, Meheus
L and Sukhatme VP: Repurposing drugs in oncology
(ReDO)-itraconazole as an anti-cancer agent. Ecancermedicalscience.
9:5212015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kurosawa M, Okabe M, Hara N, Kawamura K,
Suzuki S, Sakurada K and Asaka M: Reversal effect of itraconazole
on adriamycin and etoposide resistance in human leukemia cells. Ann
Hematol. 72:17–21. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takara K, Tanigawara Y, Komada F,
Nishiguchi K, Sakaeda T and Okumura K: Cellular pharmacokinetic
aspects of reversal effect of itraconazole on
P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm
Bull. 22:1355–1359. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shirakawa K, Takara K, Tanigawara Y,
Aoyama N, Kasuga M, Komada F, Sakaeda T and Okumura K: Interaction
of docetaxel (‘Taxotere’) with human P-glycoprotein. Jpn J Cancer
Res. 90:1380–1386. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gupta A, Unadkat JD and Mao Q:
Interactions of azole antifungal agents with the human breast
cancer resistance protein (BCRP). J Pharm Sci. 96:3226–3235. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chong CR, Xu J, Lu J, Bhat S, Sullivan DJ
Jr and Liu JO: Inhibition of angiogenesis by the antifungal drug
itraconazole. ACS Chem Biol. 2:263–270. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim J, Tang JY, Gong R, Kim J, Lee JJ,
Clemons KV, Chong CR, Chang KS, Fereshteh M, Gardner D, et al:
Itraconazole, a commonly used antifungal that inhibits Hedgehog
pathway activity and cancer growth. Cancer Cell. 17:388–399. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu J, Dang Y, Ren YR and Liu JO:
Cholesterol trafficking is required for mTOR activation in
endothelial cells. Proc Natl Acad Sci USA. 107:pp. 4764–4769. 2010;
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Head SA, Shi W, Zhao L, Gorshkov K,
Pasunooti K, Chen Y, Deng Z, Li RJ, Shim JS, Tan W, et al:
Antifungal drug itraconazole targets VDAC1 to modulate the
AMPK/mTOR signaling axis in endothelial cells. Proc Natl Acad Sci
USA. 112:pp. E7276–E7285. 2015; View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu R, Li J, Zhang T, Zou L, Chen Y, Wang
K, Lei Y, Yuan K, Li Y, Lan J, et al: Itraconazole suppresses the
growth of glioblastoma through induction of autophagy: Involvement
of abnormal cholesterol trafficking. Autophagy. 10:1241–1255. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tsubamoto H, Inoue K, Sakata K, Ueda T,
Takeyama R, Shibahara H and Sonoda T: Itraconazole inhibits
Akt/mTOR signalling and proliferation in endometrial cancer cells.
Anticancer Res. 37:515–519. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liang G, Liu M, Wang Q, Shen Y, Mei H, Li
D and Liu W: Itraconazole exerts its anti-melanoma effect by
suppressing Hedgehog, Wnt, and PI3K/mTOR signaling pathways.
Oncotarget. 8:28510–28525. 2017.PubMed/NCBI
|
|
15
|
Kim J, Aftab BT, Tang JY, Kim D, Lee AH,
Rezaee M, Kim J, Chen B, King EM, Borodovsky A, et al: Itraconazole
and arsenic trioxide inhibit Hedgehog pathway activation and tumor
growth associated with acquired resistance to smoothened
antagonists. Cancer Cell. 23:23–34. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
You M, Varona-Santos J, Singh S, Robbins
DJ, Savaraj N and Nguyen DM: Targeting of the Hedgehog signal
transduction pathway suppresses survival of malignant pleural
mesothelioma cells in vitro. J Thorac Cardiovasc Surg. 147:508–516.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang X, Wei S, Zhao Y, Shi C, Liu P, Zhang
C, Lei Y, Zhang B, Bai B, Huang Y and Zhang H: Anti-proliferation
of breast cancer cells with itraconazole: Hedgehog pathway
inhibition induces apoptosis and autophagic cell death. Cancer
Lett. 385:128–136. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Y, Yao Y, Liu H, Ma X, Lv T, Yuan D,
Xiao X, Yin J and Song Y: Itraconazole can inhibit malignant
pleural effusion by suppressing lymphangiogenesis in mice. Trans
Lung Cancer Res. 4:27–35. 2015.
|
|
19
|
Nacev BA, Grassi P, Dell A, Haslam SM and
Liu JO: The antifungal drug itraconazole inhibits vascular
endothelial growth factor receptor 2 (VEGFR2) glycosylation,
trafficking, and signaling in endothelial cells. J Biol Chem.
286:44045–44056. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hara M, Nagasaki T, Shiga K and Takeyama
H: Suppression of cancer-associated fibroblasts and endothelial
cells by itraconazole in bevacizumab-resistant gastrointestinal
cancer. Anticancer Res. 36:169–177. 2016.PubMed/NCBI
|
|
21
|
White CP: On the occurrence of crystals in
tumours. J Pathol Bacteriol. 13:3–10. 1909. View Article : Google Scholar
|
|
22
|
Kuwano M, Kamiya T, Endo H and Komiyama S:
Potentiation of 5-fluorouracil, chromomycin A3, and bleomycin by
amphotericin B or polymyxin B in transformed fibroblastic cells.
Antimicrob Agents Chemother. 3:580–584. 1973. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ikezaki K, Akiyama S, Miyazaki C, Kimura G
and Kuwano M: Imidazole-resistant phenotype and virus
transformation in cultured rat cells. Cancer Res. 44:1791–1795.
1984.PubMed/NCBI
|
|
24
|
Beloribi-Djefaflia S, Vasseur S and
Guillaumond F: Lipid metabolic reprogramming in cancer cells.
Oncogenesis. 5:e1892016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Calay D, Vind-Kezunovic D, Frankart A,
Lambert S, Poumay Y and Gniadecki R: Inhibition of Akt signaling by
exclusion from lipid rafts in normal and transformed epidermal
keratinocytes. J Invest Dermatol. 130:1136–1145. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Head SA, Shi WQ, Yang EJ, Nacev BA, Hong
SY, Pasunooti KK, Li RJ, Shim JS and Liu JO: Simultaneous targeting
of NPC1 and VDAC1 by itraconazole leads to synergistic inhibition
of mTOR signaling and angiogenesis. ACS Chem Biol. 12:174–182.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gallegos AM, Atshaves BP, Storey SM,
Starodub O, Petrescu AD, Huang H, McIntosh AL, Martin GG, Chao H,
Kier AB and Schroeder F: Gene structure, intracellular
localization, and functional roles of sterol carrier protein-2.
Prog Lipid Res. 40:498–563. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Plaks V, Kong N and Werb Z: The cancer
stem cell niche: How essential is the niche in regulating stemness
of tumor cells? Cell Stem Cell. 16:225–238. 2915. View Article : Google Scholar
|
|
29
|
Kalluri R and Zeisberg M: Fibroblasts in
cancer. Nat Rev Cancer. 6:392–401. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schmitz G and Orsó E: CD14 signalling in
lipid rafts: New ligands and co-receptors. Curr Opin Lipidol.
13:513–521. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Martinez-Outschoorn UE, Sotgia F and
Lisanti MP: Caveolae and signalling in cancer. Nat Rev Cancer.
15:225–237. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Frey T and De Maio A: The antifungal agent
itraconazole induces the accumulation of high mannose glycoproteins
in macrophages. J Biol Chem. 284:16882–16890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vreugdenhil G, Van Dijke BJ, Donnelly JP,
Novakova IR, Raemaekers JM, Hoogkamp-Korstanje MA, Koster M and de
Pauw BE: Efficacy of itraconazole in the prevention of fungal
infections among neutropenic patients with hematologic malignancies
and intensive chemotherapy. A double blind, placebo controlled
study. Leuk Lymphoma. 11:353–358. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gupta S, Kim J and Gollapudi S: Reversal
of daunorubicin resistance in P388/ADR cells by itraconazole. J
Clin Invest. 87:1467–1469. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vreugdenhil G, Raemaekers JM, van Dijke BJ
and de Pauw BE: Itraconazole and multidrug resistance: Possible
effects on remission rate and disease-free survival in acute
leukemia. Ann Hematol. 67:107–109. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tsubamoto H, Sonoda T, Yamasaki M and
Inoue K: Impact of combination chemotherapy with itraconazole on
survival of patients with refractory ovarian cancer. Anticancer
Res. 34:2481–2487. 2014.PubMed/NCBI
|
|
37
|
Tsubamoto H, Sonoda T, Yamasaki M and
Inoue K: Impact of combination chemotherapy with itraconazole on
survival for patients with recurrent or persistent ovarian clear
cell carcinoma. Anticancer Res. 34:2007–2014. 2014.PubMed/NCBI
|
|
38
|
Tsubamoto H, Sonoda T and Inoue K: Impact
of itraconazole on the survival of heavily pre-treated patients
with triple-negative breast cancer. Anticancer Res. 34:3839–3844.
2014.PubMed/NCBI
|
|
39
|
Tsubamoto H, Sonoda T, Ikuta S, Tani S,
Inoue K and Yamanaka N: Combination chemotherapy with itraconazole
for treating metastatic pancreatic cancer in the second-line or
additional setting. Anticancer Res. 35:4191–4196. 2015.PubMed/NCBI
|
|
40
|
Tsubamoto H, Sonoda T, Ikuta S, Tani S,
Inoue K and Yamanaka N: Impact of itraconazole after first-line
chemotherapy on survival of patients with metastatic biliary tract
cancer. Anticancer Res. 35:4923–4927. 2015.PubMed/NCBI
|
|
41
|
Chung FS, Santiago JS, Jesus MF, Trinidad
CV and See MF: Disrupting P-glycoprotein function in clinical
settings: What can we learn from the fundamental aspects of this
transporter? Am J Cancer Res. 6:1583–1598. 2016.PubMed/NCBI
|
|
42
|
Lhommé C, Joly F, Walker JL, Lissoni AA,
Nicoletto MO, Manikhas GM, Baekelandt MM, Gordon AN, Fracasso PM,
Mietlowski WL, et al: Phase III study of valspodar (PSC 833)
combined with paclitaxel and carboplatin compared with paclitaxel
and carboplatin alone in patients with stage IV or suboptimally
debulked stage III epithelial ovarian cancer or primary peritoneal
cancer. J Clin Oncol. 26:2674–2682. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rudin CM, Brahmer JR, Juergens RA, Hann
CL, Ettinger DS, Sebree R, Smith R, Aftab BT, Huang P and Liu JO:
Phase 2 study of pemetrexed and itraconazole as second-line therapy
for metastatic nonsquamous non-small-cell lung cancer. J Thorac
Oncol. 8:619–623. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Roviello G, Bachelot T, Hudis CA,
Curigliano G, Reynolds AR, Petrioli R and Generali D: The role of
bevacizumab in solid tumours: A literature based meta-analysis of
randomised trials. Eur J Cancer. 75:245–258. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Garon EB, Ciuleanu TE, Arrieta O, Prabhash
K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel
J, et al: Ramucirumab plus docetaxel versus placebo plus docetaxel
for second-line treatment of stage IV non-small-cell lung cancer
after disease progression on platinum-based therapy (REVEL): A
multicentre, double-blind, randomised phase 3 trial. Lancet.
384:665–673. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Fuchs CS, Tomasek J, Yong CJ, Dumitru F,
Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry
DR, et al: Ramucirumab monotherapy for previously treated advanced
gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An
international, randomised, multicentre, placebo-controlled, phase 3
trial. Lancet. 383:31–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wilke H, Muro K, Van Cutsem E, Oh SC,
Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et
al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in
patients with previously treated advanced gastric or
gastro-oesophageal junction adenocarcinoma (RAINBOW): A
double-blind, randomised phase 3 trial. Lancet Oncol. 15:1224–1235.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tabernero J, Yoshino T, Cohn AL,
Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy
DC, Van Cutsem E, Grothey A, et al: Ramucirumab versus placebo in
combination with second-line FOLFIRI in patients with metastatic
colorectal carcinoma that progressed during or after first-line
therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine
(RAISE): A randomised, double-blind, multicentre, phase 3 study.
Lancet Oncol. 16:499–508. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Antonarakis ES, Heath EI, Smith DC,
Rathkopf D, Blackford AL, Danila DC, King S, Frost A, Ajiboye AS,
Zhao M, et al: Repurposing itraconazole as a treatment for advanced
prostate cancer: A noncomparative randomized phase II trial in men
with metastatic castration-resistant prostate cancer. Oncologist.
18:163–173. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
NCCN: Clinical practice guidelines in
oncology, basal cell skin cancer, version 1. 2017.https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdfApril
20–2017
|
|
51
|
Kim DJ, Kim J, Spaunhurst K, Montoya J,
Khodosh R, Chandra K, Fu T, Gilliam A, Molgo M, Beachy PA and Tang
JY: Open-label, exploratory phase II trial of oral itraconazole for
the treatment of basal cell carcinoma. J Clin Oncol. 32:745–751.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhou BB, Zhang H, Damelin M, Geles KG,
Grindley JC and Dirks PB: Tumour-initiating cells: Challenges and
opportunities for anticancer drug discovery. Nat Rev Drug Discov.
8:806–823. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhao J: Cancer stem cells and
chemoresistance: The smartest survives the raid. Pharmacol Ther.
160:145–158. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ahmed M, Chaudhari K, Babaei-Jadidi R,
Dekker LV and Nateri A Shams: Concise Review: Emerging drugs
targeting epithelial cancer stem-like cells. Stem Cells.
35:839–850. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Li Y, Rogoff HA, Keates S, Gao Y,
Murikipudi S, Mikule K, Leggett D, Li W, Pardee AB and Li CJ:
Suppression of cancer relapse and metastasis by inhibiting cancer
stemness. Proc Natl Acad Sci USA. 112:pp. 1839–1844. 2015;
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Jonker DJ, Nott L, Yoshino T, Gill S,
Shapiro J, Ohtsu A, Zalcerg J, vickers MM, Wei A, Gao Y, et al: A
randomized phase III study of napabucasin [BBI608] (NAPA) vs
placebo (PBO) in patients (pts) with pretreated advanced colorectal
cancer (ACRC): The CCTG/AGITG CO.23 trial. Ann Oncol. 27 Suppl
6:S454O2016. View Article : Google Scholar
|
